Ideas catalog
Every idea we've derived from recent research — the ones marked “Prototype” come with a live demo you can try.
A generic digital health application that translates a well-known clinical protocol into a standard app, lacking a unique technical moat or a specific high-urgency wedge.
A single high-quality RCT backs a genuinely differentiated AUD treatment, but Schedule I regulatory barriers, absent replication studies, and thin IP moats make near-term commercial scale highly uncertain.
A niche utility tool that leverages a specific mission's data, but lacks a clear commercial business model given that the target beneficiaries typically build these tools in-house.
A focused planning SaaS for vertiport siting built directly on a validated 990-city UAM demand methodology, but the market is nascent, slow-moving, and dependent on an industry that hasn't commercially launched.
A useful but generic application of existing IPCC data that lacks a proprietary technical moat and faces high friction in municipal procurement.
A timely but generic risk-modeling tool that lacks a proprietary data edge and faces heavy competition from established ESG and actuarial software.
A high-risk psychological 'trick' that leverages a single study to deceive users into thinking an AI is human, creating significant ethical and regulatory liabilities in the mental health space.
A clinically grounded orthodontic outcomes registry with a real niche, but it faces hard data-aggregation hurdles and an uncertain willingness-to-pay in a relatively narrow vertical.
Backed by 3 papers
A focused hardware play targeting a critical bottleneck in UAM power density, though it relies on a generic review paper rather than a specific technical breakthrough.
A timely source-capture device for tire-wear particles riding the Euro 7 non-exhaust regulatory wave, but built on a single demonstrator paper and facing serious integration, durability, and OEM design-cycle hurdles.
A moderately useful UI enhancement for BI tools that lacks a strong competitive moat and faces significant headwinds from existing 'drill-down' features in market leaders.
Strong convergent evidence for the underlying gap, but the five-module multi-persona platform is over-scoped, the near-term market is tiny and regulatory-dependent, and dominant trial sponsors are likely to build proprietary tools rather than buy.
Backed by 6 papers
Compelling clinical evidence and a clear unmet need are fatally undermined by the FDA's August 2024 Complete Response Letter rejecting Lykos's NDA, which renders the 'why now' premise commercially inert for the foreseeable future.
A focused, regulation-ready product grounded in a real demonstrator, but the evidence base is thin (one prototype study) and critical commercialization hurdles—retrofit thermal management, weight penalties, and incumbent Tier 1 brake OEM competition—are unaddressed.
Backed by 2 papers
A compliance-driven SDK with a real regulatory tailwind and a focused product concept, but it rests on a single 30-year-old theoretical source with no modern digital-context efficacy data, and faces a crowded incumbent RG-tooling market it doesn't clearly differentiate from.
A high-concept visualization tool that lacks a specific high-urgency problem, risking becoming a 'solution in search of a problem' despite the technical feasibility.
A highly specialized mathematical application for niche precision hardware, though it lacks a clear commercial bridge from abstract wavelet theory to a tangible product.
A focused, well-motivated compliance-monitoring sensor for removable orthodontic appliances, but the concept already exists commercially (e.g., TheraMon/Smart Retainer microsensors), undermining its differentiation.
Backed by 2 papers
A low-complexity alert system that leverages existing data but lacks a sustainable commercial model and a strong technical moat.
A niche optimization tool targeting a growing regulatory concern (TRWP), but currently lacks a clear mechanism for real-time pressure adjustment in production vehicles.
Backed by 2 papers